Findings of Scientific Misconduct, 48747 [E9-23046]

Download as PDF Federal Register / Vol. 74, No. 184 / Thursday, September 24, 2009 / Notices FOR FURTHER INFORMATION CONTACT: Jeritta Parnell, Contract Policy Division, GSA (202) 501–4082 or e-mail jeritta.parnell@gsa.gov. SUPPLEMENTARY INFORMATION: A. Purpose Value engineering is the technique by which contractors (1) voluntarily suggest methods for performing more economically and share in any resulting savings or (2) are required to establish a program to identify and submit to the Government methods for performing more economically. These recommendations are submitted to the Government as value engineering change proposals (VECP’s) and they must include specific information. This information is needed to enable the Government to evaluate the VECP and, if accepted, to arrange for an equitable sharing plan. B. Annual Reporting Burden Respondents: 400. Responses per Respondent: 4. Annual Responses: 1,600. Hours per Response: 30. Total Burden Hours: 48,000. Obtaining Copies of Proposals: Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat (VPR), 1800 F Street, NW., Room 4041, Washington, DC 20405, telephone (202) 501–4755. Please cite OMB Control No. 9000–0027, Value Engineering Requirements, in all correspondence. Dated: September 17, 2009. Al Matera, Director, Acquisition Policy Division. [FR Doc. E9–23089 Filed 9–23–09; 8:45 am] BILLING CODE 6820–EP–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Scientific Misconduct Office of the Secretary, HHS. Notice. AGENCY: srobinson on DSKHWCL6B1PROD with NOTICES ACTION: SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Nagendra S. Ningaraj, PhD, Vanderbilt University School of Medicine: Based on the reports of an investigation conducted by Vanderbilt University School of Medicine (VUSM) and additional analysis by the Division VerDate Nov<24>2008 16:27 Sep 23, 2009 Jkt 217001 of Investigative Oversight (DIO), ORI, in its oversight review, found that Nagendra S. Ningaraj, PhD, former Associate Professor of Neurological Surgery and Cancer Biology, VUSM, engaged in scientific misconduct by falsifying MALDI–MS images and mass spectral tracings and associated text in Figure 21 reported in National Cancer Institute (NCI), National Institutes of Health (NIH), grant application 1 U54 CA119421–01 and by falsifying MALDI– MS images in a presentation during the American Association for Cancer Research (AACR) meeting held on April 16–20, 2005, which cited support from NCI, NIH, grants R25 CA92943 and P50 CA098131. Specifically, ORI found that: 1. Respondent reversed the images for the control and minoxidil-treated brains in Figure 21 of the 1 U54 CA119421–01 grant application, claiming that minoxidil increased delivery of Gleevec to the tumor. Respondent also reversed the same images in a presentation during the AACR meeting in April 2005. 2. In Figure 21 of the 1 U54 CA119421–01 grant application, Respondent reported mass spectral tracings as having been obtained from brain tumors in Gleevec-treated mice that had been pretreated with minoxidil, while in fact they were pretreated with another potassium channel opener, NS1619, and Respondent falsely stated the minoxidil pretreatment caused an 8-fold increase in Gleevec delivery to brain tumors (compared to nonminoxidil pretreated tumors). 3. Respondent further falsified Figure 21 of the 1 U54 CA119421–01 grant application by juxtaposing the reversed MALDI–MS images (obtained with mioxidil) with the mass spectral tracings (obtained with NS1619) in the same figure and by failing to report that the images and spectra in the figure were actually obtained in totally different experiments, performed on different dates and with different K+ agonist pretreatments. Dr. Ningaraj has entered into a Voluntary Settlement Agreement in which he has voluntarily agreed, for a period of three (3) years, beginning on August 31, 2009: (1) To be prohibited from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; (2) That any institution that submits an application for PHS support for a research project on which the Respondent’s participation is proposed or which uses him in any capacity on PHS-supported research or that submits a report of PHS-funded research on PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 48747 which he is involved must submit a plan for supervision of his duties to the funding agency for approval no later than a month before the scheduled funding; the supervisory plan must be designed to ensure the scientific integrity of his research contribution; a copy of the supervisory plan also must be submitted to ORI by the institution; Respondent agrees that he will not participate in any PHS-supported research until such a supervisory plan is submitted to ORI; and (3) Respondent will ensure that any institution employing him submits, in conjunction with each application for PHS funds or any report, manuscript, or abstract of PHS-funded research in which he is involved, a certification that the data provided by him are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application or report. Respondent must ensure that the institution send the certification to ORI. The certification shall be submitted no later than one month before funding and concurrently with any report, manuscript, or abstract. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. E9–23046 Filed 9–23–09; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Child Health and Human Development; Submission for OMB Review; Comment Request; NEXT Generation Health Study SUMMARY: Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institute of Child Health and Human Development (NICHD), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the Federal Register on July 17, 2009, Volume 74, Number 136, pages 34760– 34761 and allowed 60 days for public comment. Two public comments were received. One questioned the value of E:\FR\FM\24SEN1.SGM 24SEN1

Agencies

[Federal Register Volume 74, Number 184 (Thursday, September 24, 2009)]
[Notices]
[Page 48747]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-23046]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) and the Assistant Secretary for Health have taken final action in 
the following case:
    Nagendra S. Ningaraj, PhD, Vanderbilt University School of 
Medicine: Based on the reports of an investigation conducted by 
Vanderbilt University School of Medicine (VUSM) and additional analysis 
by the Division of Investigative Oversight (DIO), ORI, in its oversight 
review, found that Nagendra S. Ningaraj, PhD, former Associate 
Professor of Neurological Surgery and Cancer Biology, VUSM, engaged in 
scientific misconduct by falsifying MALDI-MS images and mass spectral 
tracings and associated text in Figure 21 reported in National Cancer 
Institute (NCI), National Institutes of Health (NIH), grant application 
1 U54 CA119421-01 and by falsifying MALDI-MS images in a presentation 
during the American Association for Cancer Research (AACR) meeting held 
on April 16-20, 2005, which cited support from NCI, NIH, grants R25 
CA92943 and P50 CA098131.
    Specifically, ORI found that:
    1. Respondent reversed the images for the control and minoxidil-
treated brains in Figure 21 of the 1 U54 CA119421-01 grant application, 
claiming that minoxidil increased delivery of Gleevec to the tumor. 
Respondent also reversed the same images in a presentation during the 
AACR meeting in April 2005.
    2. In Figure 21 of the 1 U54 CA119421-01 grant application, 
Respondent reported mass spectral tracings as having been obtained from 
brain tumors in Gleevec-treated mice that had been pretreated with 
minoxidil, while in fact they were pretreated with another potassium 
channel opener, NS1619, and Respondent falsely stated the minoxidil 
pretreatment caused an 8-fold increase in Gleevec delivery to brain 
tumors (compared to non-minoxidil pretreated tumors).
    3. Respondent further falsified Figure 21 of the 1 U54 CA119421-01 
grant application by juxtaposing the reversed MALDI-MS images (obtained 
with mioxidil) with the mass spectral tracings (obtained with NS1619) 
in the same figure and by failing to report that the images and spectra 
in the figure were actually obtained in totally different experiments, 
performed on different dates and with different K\+\ agonist 
pretreatments.
    Dr. Ningaraj has entered into a Voluntary Settlement Agreement in 
which he has voluntarily agreed, for a period of three (3) years, 
beginning on August 31, 2009:
    (1) To be prohibited from serving in any advisory capacity to PHS, 
including but not limited to service on any PHS advisory committee, 
board, and/or peer review committee, or as a consultant;
    (2) That any institution that submits an application for PHS 
support for a research project on which the Respondent's participation 
is proposed or which uses him in any capacity on PHS-supported research 
or that submits a report of PHS-funded research on which he is involved 
must submit a plan for supervision of his duties to the funding agency 
for approval no later than a month before the scheduled funding; the 
supervisory plan must be designed to ensure the scientific integrity of 
his research contribution; a copy of the supervisory plan also must be 
submitted to ORI by the institution; Respondent agrees that he will not 
participate in any PHS-supported research until such a supervisory plan 
is submitted to ORI; and
    (3) Respondent will ensure that any institution employing him 
submits, in conjunction with each application for PHS funds or any 
report, manuscript, or abstract of PHS-funded research in which he is 
involved, a certification that the data provided by him are based on 
actual experiments or are otherwise legitimately derived and that the 
data, procedures, and methodology are accurately reported in the 
application or report. Respondent must ensure that the institution send 
the certification to ORI. The certification shall be submitted no later 
than one month before funding and concurrently with any report, 
manuscript, or abstract.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. E9-23046 Filed 9-23-09; 8:45 am]
BILLING CODE 4150-31-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.